A novel VEGF decoy receptor targeting PD‐L1‐expression CAFs via the PD‐L1 directed PGF/VEGF blockade could improve the efficacy of chemotherapy.[33] In phase I trials, long‐term disease control was achieved by some patients with advanced solid tumors who were treated by PGF monoclonal antibody.[34, 35] Therefore, targeting PGF can be a promising strategy for gastric cancer patients with high DNB score or PGF level and should be validated in our future studies. Here, VEGFA is linked to gastric cancer.